Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method For Treating Cancer

Inactive Publication Date: 2009-12-17
ALLEN BARRY JOHN
View PDF2 Cites 22 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0006]According to a first aspect of the present invention, there is provided a method for the treatment of metastatic cancer, wherein said method comprises administering to a subject a therapeutically effective amount of a killing agent conjugated to a protein, and wherein said killing agent conjugated to said protein binds to at least one cell associated with the metastatic cancer.

Problems solved by technology

However, once cancer cells have dispersed, therapy is at best palliative only.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method For Treating Cancer
  • Method For Treating Cancer
  • Method For Treating Cancer

Examples

Experimental program
Comparison scheme
Effect test

example 1

General Methods

1.1 Patient Enrolment

[0106]Clinical investigators invited eligible melanoma patients to participate in the trial. The patients were informed about the objectives and risks of the study and were required to sign the consent form before study specific screening procedures were performed. This study was approved by the South Eastern Sydney Area Ethics Committee (00 / 76 Allen) and the NSW Radiation Safety Council and Environmental Protection Authority.

[0107]Criteria for entry into the study were resected patients with documented AJCC / UICC (American Joint Committee on Cancer / International Union against Cancer) stage IV melanoma, at least 18 years of age with expected survival of at least 6 months and adequate haematological, renal and liver functions. Patients had to be able to provide informed consent and to have a Karnofsky Performance Status of at least 70%. Patients were excluded if they had active brain metastasis, active infection or serious medical comorbidity, were ...

example 2a

Intralesional Toxicity

[0130]Enrolment progressed in a stepwise fashion through the planned dose levels. The patients received intralesional injections of the AIC starting from 50 μCi increasing in steps of 100 μCi. The maximum tolerated dose (MTD) was not reached as an effective intralesional dose was obtained at quite low activities. There were no adverse events. In general, the full blood counts and clinical chemistry did not change from the baseline values. There was no significant red cell abnormality nor change in white blood cells and platelets from baseline. Occasional reactive lymphocytes were seen at higher doses. Slight polychromasia was seen in some patients showing fast platelet turnover. Occasional reactive lymphocytes were seen in some patients. The haemoglobin was in the normal range at all doses. There were no significant changes in sodium, albumin and calcium, urea and creatinine at 4 weeks post-TAT. Potassium did not change and was in the normal range for all the p...

example 2b

Systemic Toxicity

[0132]Kinetics data were corrected for radioactive decay and absorbed dose in the tumour and normal tissues was calculated from the measured activities. Dosimetric analysis was based on measured kinematics using a NaI spectrometer located over the injected tumour, bladder and kidneys as well as urine activity measurements. The bi-exponential fit to the clearance of activity showed rather variable fast and slow clearance rates from the tumour. The mean intensities and exponents were found to be:

Fast clearance0.61 ± 0.090.10 ± 0.02Slow clearance0.16 ± 0.010.03 ± 0.03P value0.00020.003

[0133]These values are significantly different, indicating that the larger fraction of the AIC is cleared rapidly from the tumour, the smaller fraction being retained by receptors on the melanoma cells. Nevertheless, the intralesional AIC was very effective in delivering a high dose to the tumour while sparing other tissues, the absorbed dose being three orders of magnitude higher in the ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
thicknessaaaaaaaaaa
pHaaaaaaaaaa
sizeaaaaaaaaaa
Login to View More

Abstract

The present invention relates to methods, kits, compositions and uses thereof for treating cancer. In particular, the present invention relates to methods, kits, compositions and uses thereof for the treatment of metastatic cancer, the treatment of angiogenesis associated with metastatic cancer, inhibiting formation of vasculature associated with metastatic cancer, killing pericytes associated with metastatic cancer and killing cancer cells contiguous with tumour capillaries associated with metastatic cancer, comprising a killing agent conjugated to a protein, and wherein said killing agent conjugated to said protein binds to at least one cell associated with the metastatic cancer.

Description

TECHNICAL FIELD[0001]The present invention relates to methods, kits, compositions and uses thereof for treating cancer. In particular, the present invention relates to methods, kits, compositions and uses thereof for treating melanoma, and to methods, compounds and kits for treating metastatic cancer.BACKGROUND ART[0002]Melanoma is the third most common cancer in Australian women, the fourth most common cancer in Australian men, and the single most common cancer in the age group 15 to 44 years. It typically comprises a very aggressive malignancy that originates in the pigment cells of the skin, otherwise known as melanocytes.[0003]Furthermore, metastatic melanoma continues to be an intractable disease that usually defies every therapeutic modality. The disease is usually exacerbated when malignant cells escape from the primary tumour, enter the bloodstream and ultimately lodge in distant organs, facilitating the development of pre-angiogenic nests of metastatic cancer cells. Angioge...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K51/10A61P35/00
CPCA61K51/1045A61K51/1066A61K51/1051A61P9/00A61P35/00A61P35/04A61K51/10
Inventor ALLEN, BARRY JOHN
Owner ALLEN BARRY JOHN
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com